Lex

Can Valeant deliver Salix savings?

Valeant has agreed to buy Salix, the gastrointestinal specialist, for $14.5bn. Lex's Oliver Ralph and Robert Armstrong discuss whether the serial pharmaceuticals dealmaker's cost-cutting plans are achievable and whether its strategy is sustainable.